Repligen Corporation to Present at Upcoming September Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in three major healthcare conferences in September 2025:
- Wells Fargo Healthcare Conference (Sept 3-5, Boston) - CEO Olivier Loeillot to join analyst discussion on Sept 4 at 8:00 a.m. ET
- Deutsche Bank Healthcare Summit (Sept 10-11, NYC) - CFO Jason Garland to hold 1x1 meetings on Sept 10
- Bank of America Global Healthcare Conference (Sept 23-25, London) - CEO Olivier Loeillot to participate in analyst discussion on Sept 25 at 6:35 a.m. ET
Live webcasts will be available on Repligen's Investor Relations website with limited-time replay access.
Details
News Market Reaction – RGEN
On Aug 22, the day this news came out, RGEN closed 4.30% above the previous close.
Data tracked by StockTitan Argus for the Aug 22 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences.
- The Wells Fargo Healthcare Conference, being held September 3 – 5 in Boston. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 8:00 a.m. ET on Thursday, September 4, 2025.
- The Deutsche Bank Healthcare Summit, being held September 10 – 11 in New York. Jason Garland, Chief Financial Officer, will participate in 1x1 meetings on September 10.
- The Bank of America Global Healthcare Conference, being held September 23 – 25 in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at 6:35 a.m. ET/11:35 a.m. British Summer Time on Thursday, September 25, 2025.
A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.